Metformin versus DPP-4 inhibitors and risk of parkinsonism in type 2 diabetes: an active-comparator cohort study with a landmark design - PubMed
4 hours ago
- #Diabetes
- #Parkinson's Disease
- #Metformin
- No significant overall difference in parkinsonism risk was found between metformin and DPP-4 inhibitor initiators in type 2 diabetes patients.
- Metformin users exhibited lower all-cause mortality compared to DPP-4 inhibitor users, potentially due to residual confounding or treatment selection effects.
- Exploratory analysis suggested a lower observed risk of parkinsonism among patients surviving beyond 10 years, but this finding is hypothesis-generating and may be influenced by survival-related biases.